JP2009242273A - Oral composition capable of lowering serum ldl cholesterol level - Google Patents
Oral composition capable of lowering serum ldl cholesterol level Download PDFInfo
- Publication number
- JP2009242273A JP2009242273A JP2008089197A JP2008089197A JP2009242273A JP 2009242273 A JP2009242273 A JP 2009242273A JP 2008089197 A JP2008089197 A JP 2008089197A JP 2008089197 A JP2008089197 A JP 2008089197A JP 2009242273 A JP2009242273 A JP 2009242273A
- Authority
- JP
- Japan
- Prior art keywords
- willow
- cholesterol level
- oral composition
- ldl cholesterol
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 22
- 238000008214 LDL Cholesterol Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 241000124033 Salix Species 0.000 claims abstract description 52
- 239000000284 extract Substances 0.000 claims abstract description 41
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000921305 Salix sp. Species 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 8
- 230000035622 drinking Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241000219000 Populus Species 0.000 description 5
- 241001278097 Salix alba Species 0.000 description 5
- 241000819176 Salix japonica Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- -1 troches Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000646858 Salix arbusculoides Species 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241001481760 Erethizon dorsatum Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001278112 Populus euphratica Species 0.000 description 2
- 241000218998 Salicaceae Species 0.000 description 2
- 244000020191 Salix babylonica Species 0.000 description 2
- 240000002332 Salix daphnoides Species 0.000 description 2
- 241000119565 Salix gooddingii Species 0.000 description 2
- 241001299682 Salix purpurea Species 0.000 description 2
- 241001059835 Salix rorida Species 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000007967 peppermint flavor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000309456 Decussocarpus nagi Species 0.000 description 1
- 235000008375 Decussocarpus nagi Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 229930184510 Mallotus Natural products 0.000 description 1
- 241001060384 Mallotus <angiosperm> Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 241001528565 Malus sieboldii Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000232219 Platanista Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000168036 Populus alba Species 0.000 description 1
- 235000009769 Populus balsamifera subsp. balsamifera Nutrition 0.000 description 1
- 241000161288 Populus candicans Species 0.000 description 1
- 241001153009 Populus koreana Species 0.000 description 1
- 241000218982 Populus nigra Species 0.000 description 1
- 241000734097 Populus nigra var. italica Species 0.000 description 1
- 240000004923 Populus tremuloides Species 0.000 description 1
- 241000218981 Populus x canadensis Species 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 240000001052 Prunus maximowiczii Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000000191 Prunus tomentosa Species 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 241001249584 Salix bakko Species 0.000 description 1
- 235000015319 Salix daphnoides Nutrition 0.000 description 1
- 241000530742 Salix elaeagnos Species 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 244000176614 Salix gracilistyla var. melanostachys Species 0.000 description 1
- 241001378938 Salix humboldtiana Species 0.000 description 1
- 241001352116 Salix laevigata Species 0.000 description 1
- 241000779709 Salix matsudana Species 0.000 description 1
- 241000125000 Salix nakamurana Species 0.000 description 1
- 241000646901 Salix nummularia Species 0.000 description 1
- 235000001824 Salix pulchra Nutrition 0.000 description 1
- 241001278083 Salix reinii Species 0.000 description 1
- 241001299685 Salix schwerinii Species 0.000 description 1
- 241001278068 Salix subfragilis Species 0.000 description 1
- 241000790388 Salix udensis Species 0.000 description 1
- 241000100162 Scopelodes vulpina Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001404004 Staurothele rupifraga Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001265090 Trichys fasciculata Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、ヤナギ樹皮抽出物および/またはヤナギ芽抽出物を含有する血清中のLDLコレステロール値を低下させることを特徴とする経口組成物に関する。 The present invention relates to an oral composition characterized by reducing LDL cholesterol level in serum containing willow bark extract and / or willow bud extract.
血清中のコレステロール値、特にLDLコレステロール値が高い状態が継続すると、血管組織に変質が生じるリスクが高まることが知られている。この状態を放置すれば、脂質異常症を発症し、最終的には日本人の死因の約3割を占める心疾患や脳血管疾患を引き起こす要因にもなることから、血清中のLDLコレステロールを低減させ、低く抑えることは肝要である。しかし、近年、食生活の乱れに起因する不規則な食習慣や動物性脂質の過剰摂取などにより、年齢が上がるとともに血清中のLDLコレステロール値も上昇し、脂質異常症を発症する人が年々増加している。 It is known that if the serum cholesterol level, particularly the state of high LDL cholesterol level, continues, the risk of alteration of the vascular tissue increases. If this condition is left untreated, dyslipidemia develops and ultimately causes heart disease and cerebrovascular disease that account for about 30% of Japanese deaths, reducing serum LDL cholesterol. It is important to keep it low. However, due to irregular eating habits and excessive intake of animal lipids due to disordered dietary habits, the number of people who develop dyslipidemia increases year by year as serum LDL cholesterol levels increase. is doing.
血清中のLDLコレステロール値は食事内容に大きく影響を受けることから、食事内容を改善して血清中のLDLコレステロール値を下げる方法が有効であり、最も好ましい。しかし、食事内容を改善し、それを継続して実行することは現実には難しく、日常の食事内容を変えることなく血清中のLDLコレステロール値を下げる方法が望まれている。医薬品の服用は効果が高く、簡単に実行できるが、薬効に頼り長期間服用する人が多いため、横紋筋融解作用や肝機能障害等の副作用のリスクが存在するだけでなく、昨今の医療費増大を増長することから好ましくない。 Since the LDL cholesterol level in serum is greatly affected by the meal content, a method of improving the meal content and lowering the serum LDL cholesterol level is effective and most preferred. However, it is actually difficult to improve and continuously execute the meal content, and a method for lowering the LDL cholesterol level in serum without changing the daily meal content is desired. Although taking medicines is highly effective and easy to implement, there are many people who take medicines for long periods of time depending on their efficacy, so there is a risk of side effects such as rhabdomyolysis and liver dysfunction. This is not preferable because it increases the cost increase.
そこで、実行が容易でかつ長期間実施しても安全性上の課題が生じない方法として、食品由来の素材を有効成分とする機能性食品の開発が進められている。例えば、特許文献1には、シジミ可食部の抽出物を有効成分とするコレステロール低下剤が、特許文献2には、ラクトバチルス種(Lactobacillus
sp.)の分離株を有効成分とする血清コレステロール低下組成物が、特許文献3には、卵白に含有されるペプチドを有効成分とする血清コレステロール低下剤などが提案されているが、未だ十分な効果を得るものがない。
sp. Serum cholesterol-lowering composition comprising an isolated strain of)) as an active ingredient, Patent Document 3 proposes a serum cholesterol-lowering agent containing a peptide contained in egg white as an active ingredient. There is nothing to get.
本発明の目的は、血清LDLコレステロール値の低下作用を有する経口組成物を提供することにある。 An object of the present invention is to provide an oral composition having a lowering effect on serum LDL cholesterol level.
本発明者らは上記課題を解決するためにヤナギ樹皮抽出物および/またはヤナギ芽抽出物に優れた血清中のLDLコレステロール値を低下させる効果があることを見出し、本発明を完成させた。 In order to solve the above-mentioned problems, the present inventors have found that willow bark extract and / or willow bud extract have an excellent effect of lowering LDL cholesterol level in serum, and have completed the present invention.
すなわち、本発明は下記の組成物を提供するものである。
項1.ヤナギ樹皮抽出物および/またはヤナギ芽抽出物を含有する血清中のLDLコレステロール値を低下させることを特徴とする経口組成物。
項2.「コレステロールを正常に保つことを助ける」旨が表示に付された食品であることを特徴とする請求項1に記載の経口組成物。
That is, the present invention provides the following composition.
Item 1. An oral composition characterized by lowering LDL cholesterol level in serum containing willow bark extract and / or willow bud extract.
Item 2. The oral composition according to claim 1, which is a food with a label “helping keep cholesterol normal”.
本発明によれば、血清LDLコレステロール値の低下作用を有する経口組成物を提供できる。 According to the present invention, an oral composition having a lowering effect on serum LDL cholesterol level can be provided.
以下、本発明につき更に詳細に説明する。 Hereinafter, the present invention will be described in more detail.
本発明に用いることのできるヤナギは、ヤナギ科(Salicaceae)のPopulus属又はSalix族に属する植物である。Populus属に属する植物の例としては、ウラジロハコヤナギ(別名ハクヨウ、ギンドロ;P.alba)、カナダポプラ、アメリカクロヤマナラシ(別名ヒロハハコヤナギ)、コトカケヤナギ、(P.euphratica)、オオバヤマナラシ(P.tomentosa)、チリメンドロ(P.koreana)、ドロノキ(P.maximowiczii)、ヨーロッパクロヤマナラシ(P.nigra)、セイヨウハコヤナギ(別名イタリアヤマナラシ;P.nigra var. italica)、ヤマナラシ(別名ハコヤナギ、ポプラ;P.sieboldii)、バルサムポプラ(P.tecamahaca)、シマヤマナラシ、チョウセンヤマナラシ(P.davidiana)、アメリカヤマナラシ(P.tremuloides)、P.euramericana等が挙げられる。Salix属に属する植物の例としては、セイヨウシロヤナギ(S.alba)、サイコクキツネヤナギ(S.alopochroa)、ユスラバヤナギ、シダレヤナギ(別名イトヤナギ;S.babylonica)、ヤマネコヤナギ(別名バッコヤナギ;S.bakko)、アカメヤナギ(別名マルバヤナギ;(S.chaeagnos)、コガネシダレ(S.chrysochoma)、S.daphnoides、サクリス・エラエアグスノス(S.elaeagnos Scopoli)、ポッキリヤナギ(S.futura)、カワヤナギ(別名ナガバカワヤナギ;S.gilgiana)、ネコヤナギ(S.alba)(S.gracilistyla)、クロヤナギ(S.gracilistyla var. melanostachys)、サウセ(S.humboldtiana)、イヌコリヤナギ(S.integra)、シバヤナギ(S.japonica)、シロヤナギ(S.jessoens)、キヌヤナギ(S.kinuyanagi)、コリヤナギ(S.koriyanagi)、エゾヤナギ(S.rorida)、フリソデヤナギ(S.leucopithecia)、ウンリュウヤナギ(S.matsudana f. tortuosa)、タカネイワヤナギ(別名レンゲイワヤナギ)、オオシダレヤナギ(S.ohshidare)、エゾマメヤナギ(S.nummularia ssp. pauciflora)、エゾノキヌヤナギ(S.pet-susu)、S.purpurea、コウヒリュウ、ミヤマヤナギ(別名ミネヤナギ;S.reinii)、コマイワヤナギ(S.rupifraga)、オノエヤナギ(別名カラフトヤナギ;S.sachalinensis)、コゴメヤナギ(S.serissaefolia)、シライヤナギ(S.shirai)、Salix sp、タチヤナギ(S.subfragilis)、ノヤナギ(別名ヒメヤナギ)、イヨウヤナギ、キツネヤナギ(別名イワヤナギ;S.vulpina)、エゾノタカネヤナギ(S.yezoalpina)等が挙げられる。ヤナギの抽出部位は樹皮および/または芽(特に新芽)を使用するが、その葉、花、果実、枝、幹等が一部混在していても良い。好ましいヤナギは、西洋ヤナギであり、中でもSalix daphnoides,Salix sp,Salix purpurea,Salix fragilix,Salix albaである。 The willows that can be used in the present invention are plants belonging to the Populus genus or Salix family of the Salicaceae family. Examples of plants belonging to the Populus genus, Mallotus Ha Koyanagi (aka marine, Populus alba; P.Alba), Canada poplar, American Black Mountain break (aka Hiro ha Koyanagi), populus euphratica, (P. euphratica), Oba Mountain leveling (P.Tomentosa) , Chilemendro (P.koreana), Dronoki (P.maximowiczii), European black willow (P.nigra), Atlantic willow ( aka Italian porcupine; P.nigra var. Italica), Porcupine ( aka poplar; poplar; P. sieboldii) , Balsam poplar (P. tecamahaca), long-tailed porcupine, P. davidiana, P. tremuloides, P. euramericana and the like. Examples of plants belonging to the genus Salix include: S. alba, S. alopochroa, Yusura willow, Weeping willow ( also known as S. babylonica), Siberian willow ( also known as S. bakko) , Red willow ( aka S. chaeagnos), S. chrysochoma, S. daphnoides, S. elaeagnos Scopoli, S. futura, S. futura, aka Sana. gilgiana), cat willow (S. alba) (S. gracilistyla), black willow (S. gracilistyla var. melanostachys), saus (S. humboldtiana), Incoryana nagi (S. integral), white willow (S. japonica), white willow (S. jessoens), Kinuyanagi (S.kinuyanagi), Koryanagi (S.koriyanagi), Ezo willow (S.rorida), Frisode willow ( S. leucopithecia), Unryu willow (S. matsudana f. Tortuosa), Takane willow ( also known as Rengay willow), S.ohshidare, S. nummularia ssp. Pauciflora, Ezo. susu), S. purpurea, Kou Hiryu, Miyama willow ( aka S. reinii), Komai willow (S. rupifraga), Onoe willow (aka Karafuto willow; S. sachalinensis), S. serissaefolia (S. serissaefolia), Shirai willow , Salix sp, S. subfragilis, Japanese willow (also known as Japanese willow), Japanese willow, Japanese willow ( also known as S. vulpina), S. yezoalpina, etc. The extraction sites of willow are bark and barley. / Or buds (especially new shoots) are used, but their leaves, flowers, fruits, branches, trunks, etc. are partly mixed Good. Preferred willow is Western willow, among others Salix daphnoides, Salix sp, Salix purpurea, Salix fragilix, a Salix alba.
本発明においてヤナギ樹皮抽出物やヤナギ芽抽出物は、上記のヤナギの樹皮や芽を必要に応じて、細切り、乾燥、粉砕などの抽出に適した形状に処理を行ってから抽出することが好ましい。通常、上記処理されたヤナギ抽出部位を抽出溶媒を用い、必要に応じて静置、振とう、超音波照射、加熱、加圧等やそれらを組みあわせることによって抽出する。好ましくは、ヤナギ抽出部位を抽出溶媒に浸漬し、振とうまたは攪拌する方法である。 In the present invention, the willow bark extract or willow bud extract is preferably extracted after processing the willow bark and buds into a shape suitable for extraction, such as shredding, drying, and grinding, as necessary. . Usually, the treated willow extraction site is extracted by using an extraction solvent by allowing it to stand, shake, irradiate with ultrasonic waves, heat, pressurize, etc. or a combination thereof. Preferably, the willow extraction site is immersed in an extraction solvent and shaken or stirred.
抽出溶媒としては、通常水、有機溶媒などを単独又は2種以上を併用して用いる。有機溶媒は、通常、エタノール、プロパノール、イソプロパノール、ブタノール等の低級アルコール類;ポリエチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ジプロピレングリコールなどの多価アルコール類;酢酸エチル、酢酸ブチルなどのエステル類;アセトン、メチルエチルケトンなどのケトン類;CO2などの超臨界流体などが使用できる。好ましい抽出溶媒としては水又はエタノールであり、単独で又は両者を組み合わせ混合して使用できる。より好ましい抽出溶媒は水である。 As the extraction solvent, water, an organic solvent or the like is usually used alone or in combination of two or more. Organic solvents are usually lower alcohols such as ethanol, propanol, isopropanol and butanol; polyhydric alcohols such as polyethylene glycol, propylene glycol, 1,3-butylene glycol and dipropylene glycol; esters such as ethyl acetate and butyl acetate. Ketones such as acetone and methyl ethyl ketone; Supercritical fluid such as CO 2 can be used. A preferred extraction solvent is water or ethanol, which can be used alone or in combination. A more preferred extraction solvent is water.
抽出温度は、通常3〜溶媒の沸点である。抽出時間は、抽出溶媒の種類、抽出温度、ヤナギ抽出部位の抽出時の形態などによって異なるが、通常1時間〜7日間、好ましくは2時間〜3日間である。また、必要に応じて加圧することもできる。 The extraction temperature is usually 3 to the boiling point of the solvent. The extraction time varies depending on the type of extraction solvent, the extraction temperature, the form of the willow extraction site, etc., but is usually 1 hour to 7 days, preferably 2 hours to 3 days. Moreover, it can also pressurize as needed.
抽出物は、そのままでも本発明におけるヤナギ樹皮抽出物および/またはヤナギ芽抽出物として使用することができるが、濃縮、乾固、凍結乾燥したものを、水、有機溶媒等に溶解したり、抽出物の有する効果を損なわない範囲で脱色、脱臭、脱塩などの精製処理を行ったり、液・液分配。カラムクロマトグラフィによる分画処理などを行って得られたものを使用することもできる。また、ヤナギ樹皮抽出物および/またはヤナギ芽抽出物をリポソームなどの担体やマイクロカプセルなどに内包させて使用することもできる。 The extract can be used as it is as the willow bark extract and / or willow bud extract in the present invention, but the concentrated, dried, freeze-dried extract can be dissolved in water, an organic solvent or the like, or extracted. Performs purification processes such as decolorization, deodorization, and desalting as long as the effects of the product are not impaired, and liquid / liquid distribution. What was obtained by performing the fractionation process by column chromatography etc. can also be used. Moreover, a willow bark extract and / or a willow bud extract can be used by being encapsulated in a carrier such as a liposome or a microcapsule.
本発明の血清中のLDLコレステロール値を低下させる経口組成物におけるヤナギ樹皮抽出物および/またはヤナギ芽抽出物の含有量は、0.0001〜50重量%、好ましくは0.01〜30重量%、より好ましくは0.5〜10重量%である。 The content of the willow bark extract and / or willow bud extract in the oral composition for lowering the LDL cholesterol level in the serum of the present invention is 0.0001 to 50% by weight, preferably 0.01 to 30% by weight, More preferably, it is 0.5 to 10% by weight.
本発明の経口組成物は、使用目的などに応じて経口摂取に適した形態、例えば、液剤、ドリンク剤、錠剤、顆粒剤、細粒剤、粉剤などの固形剤あるいは当該液剤又は固形剤を封入したカプセル剤、口腔用スプレイ、トローチなどの形態のほか、通常食品で用いられる様々な形態をとることができる。 The oral composition of the present invention is in a form suitable for oral intake depending on the purpose of use, for example, a solid agent such as a liquid, a drink, a tablet, a granule, a fine granule, a powder, or the liquid or solid In addition to the capsules, oral sprays, and troches, various forms commonly used in foods can be used.
更に錠剤などの固形剤には必要に応じ通常の錠皮を施した錠剤、例えば糖衣錠、ゼラチン被包錠、フィルムコーティング錠、二重錠、多層錠などとすることができる。液体製剤は水性または油性の懸濁液、液状、シロップ、エキシリル剤であってもよく、通常の担体、添加剤などを用いて常法に従い、調製することができる。 Furthermore, as a solid agent such as a tablet, a tablet with a normal tablet skin, for example, a sugar-coated tablet, a gelatin-encapsulated tablet, a film-coated tablet, a double tablet, or a multilayer tablet can be used as necessary. The liquid preparation may be an aqueous or oily suspension, liquid, syrup, or exylylline, and can be prepared according to a conventional method using normal carriers, additives and the like.
好ましい製剤の形態は錠剤、トローチ、顆粒剤、カプセル剤、ドリンク剤であり、より好ましい製剤の形態は、錠剤、顆粒剤またはドリンク剤である。 Preferable preparation forms are tablets, troches, granules, capsules, drinks, and more preferable preparation forms are tablets, granules or drinks.
本発明の経口組成物は、医薬品や食品として許容される食材や添加物を含むことができる。例えば、糖質(糖類、炭水化物など)、脂質、たん白質、ミネラル類、ビタミン類、食物繊維等の他の栄養成分のほか、食品としての形態や機能を付与するのに必要な成分、(例えば嬌味成分、賦形成分、静菌性成分、色素成分、各種調味料素材、など)や通常の製剤化に用いられる添加剤(パラチノース、マルチトール、乳糖等の賦形剤、サッカリン、ステビア等の甘味料、ステアリン酸マグネシウム、ショ糖脂肪酸エステル等の滑沢剤、クエン酸等の酸味料、塩化亜鉛、粉末茶等の矯味剤、着香剤)、動植物エキス、各種薬効成分などが挙げられる。 The oral composition of the present invention can contain foods and additives acceptable as pharmaceuticals and foods. For example, in addition to other nutritional components such as carbohydrates (sugars, carbohydrates, etc.), lipids, proteins, minerals, vitamins, dietary fiber, etc., ingredients necessary to impart food form and function (for example, Flavor ingredients, ingredients, bacteriostatic ingredients, pigment ingredients, various seasoning ingredients, etc.) and additives used in normal formulation (excipients such as palatinose, maltitol, lactose, saccharin, stevia, etc.) Sweeteners, magnesium stearate, lubricants such as sucrose fatty acid esters, acidulants such as citric acid, flavoring agents such as zinc chloride and powdered tea, flavoring agents), animal and plant extracts, and various medicinal ingredients. .
以下、実施例及び比較例を示して本発明を具体的に説明するが、本発明は下記実施例に限定されるものではない。なお、各例中の配合量は、特に規定がない限り重量%を示す。 EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not limited to the following Example. In addition, the compounding quantity in each example shows weight%, unless there is a prescription | regulation.
<試験例:飲用試験> <Test example: Drinking test>
試験方法
健常者16名(26〜45歳、平均年齢34.2歳;男性7名、女性9名)を被験者として試験を行なった。飲用試験は、2週間の飲用期間とその後2週間のウォッシュアウト期間を設定し、飲用期間及びウォッシュアウト期間中においては、食事制限やその他の制約などは一切設けなかった。被検物質であるヤナギ樹皮抽出物は、西洋ヤナギ樹皮抽出物(粉末)を使用した。飲用期間中、被験者は、カプセルに封入した西洋ヤナギ樹皮粉末エキスを1日につき800mgを毎日飲用した。採血は、飲用期間の開始時と終了時及びウォッシュアウト期間終了時の空腹時に実施し、血清中の総コレステロール値、HDLコレステロール値、LDLコレステロール値を測定した。測定結果の統計解析については、検査を行った週を因子としてANOVAを実施し、F値が有意であった場合、post hocテストとしてBonferroni分析を実施し、各週での有意差検定を行った。検定結果は、1%以下の危険率で有意の場合「**」、5%以下の危険率で有意の場合「*」、それ以外の場合「−」で示した。測定結果を表1に示す。
Test method The test was conducted on 16 healthy subjects (26-45 years old, mean age 34.2 years old; 7 men, 9 women). In the drinking test, a drinking period of 2 weeks and a washout period of 2 weeks were set, and there were no dietary restrictions or other restrictions during the drinking period and the washout period. The willow bark extract as the test substance was a western willow bark extract (powder). During the drinking period, subjects drank 800 mg per day of the willow bark powder extract encapsulated daily. Blood sampling was performed at the start and end of the drinking period and on the fasting time at the end of the washout period, and the total serum cholesterol level, HDL cholesterol level, and LDL cholesterol level were measured. For statistical analysis of the measurement results, ANOVA was performed using the week of the test as a factor, and when the F value was significant, Bonferroni analysis was performed as a post hoc test, and a significant difference test was performed at each week. The test result is indicated by “**” when significant at a risk rate of 1% or less, “*” when significant at a risk rate of 5% or less, and “−” otherwise. The measurement results are shown in Table 1.
試験結果
血清中のLDLコレステロール値は、西洋ヤナギ樹皮抽出物の2週間の飲用により、有意に低下し、さらにその後のウォッシュアウト期間終了時には有意に上昇し、飲用開始時の水準に戻った。一方、血清中のHDLコレステロール値には、期間中の変化は見られず、血清中の総コレステロール値はLDLコレステロール値と同様の傾向を示した。以上より、西洋ヤナギ樹皮抽出物の飲用により、血清中のHDLコレステロール値には影響を与えずに、LDLコレステロール値を低下させることがわかった。
Test results Serum LDL cholesterol levels decreased significantly after 2 weeks of consumption of the willow bark extract, and increased significantly at the end of the subsequent washout period. I'm back. On the other hand, no change was observed in the HDL cholesterol level in the serum, and the total cholesterol level in the serum showed the same tendency as the LDL cholesterol level. From the above, it has been found that drinking of a willow bark extract decreases the LDL cholesterol level without affecting the serum HDL cholesterol level.
以下に、本発明に係る処方例を記載する。 Below, the prescription example which concerns on this invention is described.
実施例1:粉末食品
成分 重量%
西洋ヤナギ樹皮抽出物 20.0%
果糖 30.0%
デキストリン 42.4%
ペパーミントフレーバー 3.0%
アスコルビン酸 2.5%
スクラロース 0.1%
レモンフレーバー 2.0%
合計 100.0%
Example 1: Powdered food
Ingredient Weight%
Western willow bark extract 20.0%
Fructose 30.0%
Dextrin 42.4%
Peppermint flavor 3.0%
Ascorbic acid 2.5%
Sucralose 0.1%
Lemon flavor 2.0%
Total 100.0%
実施例2:錠剤
成分 重量%
ガラクトース 38.0%
西洋ヤナギ芽抽出物 15.0%
結晶セルロース 21.94%
エリスリトール 10.0%
スクラロース 0.06%
クエン酸 5.0%
ハッカ 4.0%
メントール 1.0%
ショ糖脂肪酸エステル 5.0%
合計 100.0%
Example 2: Tablet
Ingredient Weight%
Galactose 38.0%
Western willow bud extract 15.0%
Crystalline cellulose 21.94%
Erythritol 10.0%
Sucralose 0.06%
Citric acid 5.0%
Minato 4.0%
Menthol 1.0%
Sucrose fatty acid ester 5.0%
Total 100.0%
実施例3:飴
成分 重量%
還元麦芽糖水飴 52.0%
乳糖 10.0%
西洋ヤナギ樹皮抽出物 5.0%
柿の葉水抽出物 5.0%
クエン酸 7.0%
ペパーミントフレーバー 1.5%
スペアミントフレーバー 1.0%
ピーチフレーバー 2.5%
精製水 16.0%
合計 100.0%
Example 3
Ingredient Weight%
Reduced maltose starch syrup 52.0%
Lactose 10.0%
Western willow bark extract 5.0%
Bamboo leaf water extract 5.0%
Citric acid 7.0%
Peppermint flavor 1.5%
Spearmint flavor 1.0%
Peach flavor 2.5%
Purified water 16.0%
Total 100.0%
実施例4:顆粒食品
成分 重量%
西洋ヤナギ樹皮/芽抽出物 10.0%
ドクダミ水抽出物 5.0%
グァバ水抽出物 5.0%
ビワ水抽出物 5.0%
デキストリン 49.8%
ブドウ糖 20.0%
アスパルテーム 0.2%
アップルフレーバー 5.0%
合計 100.0%
Example 4: Granular food
Ingredient Weight%
Western willow bark / bud extract 10.0%
Dokudami water extract 5.0%
Guava water extract 5.0%
Loquat water extract 5.0%
Dextrin 49.8%
Glucose 20.0%
Aspartame 0.2%
Apple flavor 5.0%
Total 100.0%
実施例5:チュアブル錠
成分 重量%
西洋ヤナギ樹皮抽出物 20.0%
ブドウ糖 30.0%
アスパルテーム 0.15%
エリスリトール 20.0%
結晶セルロース 22.85%
ショ糖脂肪酸エステル 4.0%
スペアミントフレーバー 3.0%
合計 100.0%
Example 5: Chewable tablets
Ingredient Weight%
Western willow bark extract 20.0%
Glucose 30.0%
Aspartame 0.15%
Erythritol 20.0%
Crystalline cellulose 22.85%
Sucrose fatty acid ester 4.0%
Spearmint flavor 3.0%
Total 100.0%
実施例6:粉末茶
成分 重量%
西洋ヤナギ樹皮抽出物 30.0%
ハトムギ水抽出物 10.0%
煎茶水抽出物 5.0%
甜茶水抽出物 3.0%
デキストリン 18.9%
ブドウ糖 20.0%
スクラロース 0.1%
粉乳 10.0%
ジンジャーフレーバー 3.0%
合計 100.0%
Example 6: Powdered tea
Ingredient Weight%
Western willow bark extract 30.0%
Pearl barley water extract 10.0%
Sencha water extract 5.0%
Coffee tea water extract 3.0%
Dextrin 18.9%
Glucose 20.0%
Sucralose 0.1%
Milk powder 10.0%
Ginger flavor 3.0%
Total 100.0%
実施例7:グミキャンディー
成分 重量%
西洋ヤナギ樹皮抽出物 10.0%
ショ糖 55.0%
ブドウ糖 10.0%
クエン酸 1.2%
ゼラチン 8.0%
l−メントール 0.1%
ジンジャーフレーバー 1.2%
精製水 14.5%
合計 100.0%
Example 7: Gummy candy
Ingredient Weight%
Western willow bark extract 10.0%
Sucrose 55.0%
Glucose 10.0%
Citric acid 1.2%
Gelatin 8.0%
l-Menthol 0.1%
Ginger flavor 1.2%
Purified water 14.5%
Total 100.0%
実施例8:カプセル剤
成分 重量%
西洋ヤナギ樹皮抽出物 65.0%
結晶セルロース 35.0%
合計 100.0%
Example 8: Capsule
Ingredient Weight%
Western willow bark extract 65.0%
Crystalline cellulose 35.0%
Total 100.0%
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008089197A JP2009242273A (en) | 2008-03-31 | 2008-03-31 | Oral composition capable of lowering serum ldl cholesterol level |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008089197A JP2009242273A (en) | 2008-03-31 | 2008-03-31 | Oral composition capable of lowering serum ldl cholesterol level |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2009242273A true JP2009242273A (en) | 2009-10-22 |
Family
ID=41304624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008089197A Pending JP2009242273A (en) | 2008-03-31 | 2008-03-31 | Oral composition capable of lowering serum ldl cholesterol level |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2009242273A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015034140A (en) * | 2013-08-08 | 2015-02-19 | サンスター株式会社 | Anti-obesity agent |
| JP2015221032A (en) * | 2014-04-30 | 2015-12-10 | 大正製薬株式会社 | Beverage |
| WO2017119353A1 (en) * | 2016-01-08 | 2017-07-13 | アサヒビール株式会社 | Food or beverage, method for producing food or beverage, and method for improving taste |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08225453A (en) * | 1994-11-28 | 1996-09-03 | Suntory Ltd | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same |
| JP2001314173A (en) * | 2000-05-09 | 2001-11-13 | Kyoto Eiyo Kagaku Kenkyusho:Kk | Composition for food |
| JP2001346545A (en) * | 2000-06-08 | 2001-12-18 | I Farm:Kk | Dietary supplement |
| JP2006273771A (en) * | 2005-03-30 | 2006-10-12 | Kobayashi Pharmaceut Co Ltd | Edible composition compounded with extract of salix sp. |
| WO2007006384A1 (en) * | 2005-07-14 | 2007-01-18 | Indena S.P.A. | Salix extract, its use and formulations containing it |
| JP2008044905A (en) * | 2006-08-18 | 2008-02-28 | Hiroshima Univ | Composition for treating solid tumors and use thereof |
-
2008
- 2008-03-31 JP JP2008089197A patent/JP2009242273A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08225453A (en) * | 1994-11-28 | 1996-09-03 | Suntory Ltd | Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same |
| JP2001314173A (en) * | 2000-05-09 | 2001-11-13 | Kyoto Eiyo Kagaku Kenkyusho:Kk | Composition for food |
| JP2001346545A (en) * | 2000-06-08 | 2001-12-18 | I Farm:Kk | Dietary supplement |
| JP2006273771A (en) * | 2005-03-30 | 2006-10-12 | Kobayashi Pharmaceut Co Ltd | Edible composition compounded with extract of salix sp. |
| WO2007006384A1 (en) * | 2005-07-14 | 2007-01-18 | Indena S.P.A. | Salix extract, its use and formulations containing it |
| JP2008044905A (en) * | 2006-08-18 | 2008-02-28 | Hiroshima Univ | Composition for treating solid tumors and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013007605; Phytotherapy Research Vol.17, No.10, 2003, p.1188-1194 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015034140A (en) * | 2013-08-08 | 2015-02-19 | サンスター株式会社 | Anti-obesity agent |
| JP2015221032A (en) * | 2014-04-30 | 2015-12-10 | 大正製薬株式会社 | Beverage |
| WO2017119353A1 (en) * | 2016-01-08 | 2017-07-13 | アサヒビール株式会社 | Food or beverage, method for producing food or beverage, and method for improving taste |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6640392B2 (en) | Obesity control composition | |
| JP2010209051A (en) | Fat absorption inhibitor | |
| JP5800446B2 (en) | Deodorant composition under weak acidity | |
| JP2009084214A (en) | Glycation inhibitor | |
| KR20180082362A (en) | Method for steamed Codonopsis lanceolate and composition for treating non-alcoholic fatty liver comprising thereof | |
| JP2015149918A (en) | beverage | |
| JP2006016390A (en) | Proanthocyanidin-containing composition | |
| JP6778026B2 (en) | Whitening agents and whitening foods and drinks containing 4'-demethylnobiletin as an active ingredient | |
| JP2009242273A (en) | Oral composition capable of lowering serum ldl cholesterol level | |
| JP6457749B2 (en) | VCAM-1 expression inhibitor | |
| JP2019216679A (en) | Polyphenol-containing extract, polyphenol-containing composition, and food composition as well as producing method thereof, method for improving stability, and method for improving water solubility | |
| JP2012131760A (en) | Fatty acid absorption inhibitor | |
| JP6913685B2 (en) | Detoxification composition for oral administration and its preparation method | |
| JPH04300836A (en) | Hepatic dysfunction preventive agent and functional food having preventive action on hepatic dysfunction | |
| JP2007277183A (en) | Composition having brain cell-activating effect by virtue of ginkgo leaf extract nano fine particle | |
| KR102006310B1 (en) | Compositions for preventing or treating atherosclerosis comprising extracts of Angelica takeshimana | |
| JP2005053818A (en) | Trypsin inhibitor | |
| JP2020189822A (en) | Medicine, quasi drug, cosmetic or food and drink composition for preventing/improving wrinkles | |
| JP5766173B2 (en) | Foods and drinks containing chlorogenic acids | |
| KR20070113330A (en) | External skin composition comprising gompi extract | |
| JP5066394B2 (en) | Method for extracting genkwanin 5-O-β-primeveroside | |
| KR102209664B1 (en) | Composition for preventing or treating skin disease comprising extract of Euonymus alatus ciliatodentatus | |
| JP5382055B2 (en) | Fat absorption inhibitor | |
| KR20250151822A (en) | A composition for improving, preventing and treating female menopausal disorder diseases comprising extract of Stewartia | |
| JP3481246B2 (en) | Bitter and astringency enhancement method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130730 |